ClinicalTrials.gg
CompletedNCT00554229ENTHUSE M1Updated Feb 8, 2016Results posted

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases

A Phase 3 interventional study of ZD4054 and Placebo in Prostate Cancer, sponsored by AstraZeneca. Completed at 199 sites in 31 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-08.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
896
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.

Enrollment
10th of 60
896 · median 110
Started
2007
with 4 others
Phase 3
17 of 91
3 open now
Registered
15th of 91
by date

Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 10th largest by enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2007, is one of 17 in phase 3, and was the 15th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Prostatic Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

Enthuse M1 is a large phase III clinical trial studying the safety and efficacy of ZD4054 (Zibotentan) in patients with hormone resistant prostate cancer and bone metastases.

  • This clinical trial will test if the Endothelin A Receptor Antagonist ZD4054 (Zibotentan) can improve survival compared with placebo.
  • ZD4054(Zibotentan) is a new type of agent, which is thought to slow tumour growth and spread by blocking Endothelin A receptor activity. This trial will look at the effects of ZD4054 (Zibotentan) in hormone resistant prostate cancer patients with bone metastases.
  • All patients participating in this clinical trial will receive existing standard prostate cancer treatments in addition to trial therapy.
  • Half the patients will receive ZD4054 (Zibotentan), and half the patients will receive placebo in addition to standard prostate cancer therapy. By participating in this trial there is a 50% chance that patients will receive an agent that may slow the progression of the tumour.
  • No patients will be deprived of standard prostate cancer therapy.
03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Hormone Resistant Prostate Cancer
  • Endothelin A Receptor Antagonist
  • Endothelin A
  • Endothelin A antagonist
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who answer TRUE to the following criteria may be eligible to participate in this trial.

  1. Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has spread to the bone (bone )
  2. Increasing Prostate Specific Antigen (PSA) over a one month period
  3. No pain, or mild pain from prostate cancer
  4. Currently receiving treatment with surgical or medical castration

Exclusion criteria

Exclusion Criteria:

Patients who answer TRUE to the following may NOT eligible to participate in this trial.

  1. Currently using opiates based pain killers)
  2. Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone)
  3. Suffering from heart failure or had a myocardial infarction within last 6 months
  4. A history of epilepsy or seizures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
896 participants (actual)

Study arms

  • Experimental
    ZD4054

    ZD4054 10 mg oral tablet once daily

    Drug: ZD4054

  • Placebo comparator
    Placebo

    Matching Placebo, oral tablets once daily

    Drug: Placebo

Interventions

  • DrugZD4054

    ZD4054 10 mg oral tablet once daily

    Also known as: Zibotentan

  • DrugPlacebo

    Matching placebo oral tablet once daily

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Median time (in months) from randomisation until death using the Kaplan-Meier method

    Time frame: From date of randomization until date of death, assessed up to 32 months

Secondary outcomes

  1. Progression Free Survival

    Median time (in months) from randomisation until clinical progression of disease, where progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline, using the Kaplan-Meier method

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 31 months

  2. Time to Use of Opiates

    Median time (in months) from randomisation until use of opiates for disease-related symptoms for a duration ≥1 week using the Kaplan-Meier method

    Time frame: From date of randomization until use of opiates for disease-related symptoms for a duration ≥1 week, assessed up to 31 months

  3. Incidence of Skeletal Related Events

    Median time (in months) from randomisation until occurrence of a skeletal related event, where skeletal related event is defined as the first occurrence of a pathological fracture, a vertebral compression fracture not related to trauma, prophylactic surgery or radiation for impending fracture or spinal cord compression, or a spinal cord compression, using the Kaplan-Meier method.

    Time frame: From date of randomization until occurrence of a skeletal related event, assessed up to 31 months

  4. Bone Metastases Formation

    Median time (in months) from randomisation to appearance of ≥4 new bone lesions using the Kaplan-Meier method

    Time frame: Patients were assessed every 12 weeks

  5. Health Related Quality of Life

    Median time (in months) from randomisation until deterioration of Health related Quality of Life using the Kaplan-Meier method, where deterioration is defined as a change from baseline of less than or equal to -6 points in Total FACT-P score maintained for 2 consecutive visits.

    Time frame: Patients were assessed at every visit

  6. Time to Prostate-specific Antigen (PSA) Progression

    Median time (in months) from randomisation to first PSA value \>50% higher than baseline of at least 5ng/ml seen in at least 2 consecutive PSA values at least 2 weeks apart using the Kaplan-Meier method.

    Time frame: Patients were assessed every 12 weeks

  7. Time to Pain Progression

    Median time (in months) from randomisation to first assessment of an increased pain event, where increased pain event is defined as the first of a patient requiring opiate medication for duration of ≥1 week for pain due to prostate cancer metastasis, pain due to metastasis that has an increase in the worst pain item of the Brief Pain Inventory (BPI) from baseline to a minimum score of 5 with no decrease in analgesic use, or pain due to metastasis requiring radionuclide therapy, radiation therapy or surgery.

    Time frame: Patients were assessed every 12 weeks

  8. Time to Initiation of Chemotherapy

    Median time (in months) from randomisation to first administration of any chemotherapy using the Kaplan-Meier method

    Time frame: Patients were assessed every 12 weeks

  9. Pharmacokinetic Characteristics of ZD4054

    Time frame: PK samples were performed at randomisation, Week 4, Week 8 and Week 12

07

Results

Posted May 31, 2012

Participant flow

896 patients with hormone-resistant prostate cancer patients and bone metastasis were recruited between 20th November 2007 and 13th February 2009.

Participant flow — Overall Study
MilestoneZD4054Placebo
Started299295
Patients who received treatment298295
Completed7370
Not completed226225
Withdrew: Lost to follow-up36
Withdrew: Withdrawal by subject2937
Withdrew: Adverse event7139
Withdrew: Protocol violation33
Withdrew: Reason not otherwise captured, eg; death119140
Withdrew: Randomised but no treatment received10

Outcome measures

PrimaryOverall Survival

Median time (in months) from randomisation until death using the Kaplan-Meier method

Time frame:
From date of randomization until date of death, assessed up to 32 months
Reported as:
Median · months
Overall Survival
monthsZD4054Placebo
Overall Survival24.5 (0.5 to 31.2)22.5 (0.5 to 29.8)
SecondaryProgression Free Survival

Median time (in months) from randomisation until clinical progression of disease, where progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline, using the Kaplan-Meier method

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 31 months
Reported as:
Median · Months
Progression Free Survival
MonthsZD4054Placebo
Progression Free Survival6.2 (2.8 to 13.8)6.5 (2.8 to 13.2)
SecondaryTime to Use of Opiates

Median time (in months) from randomisation until use of opiates for disease-related symptoms for a duration ≥1 week using the Kaplan-Meier method

Time frame:
From date of randomization until use of opiates for disease-related symptoms for a duration ≥1 week, assessed up to 31 months
Reported as:
Median · Months
Time to Use of Opiates
MonthsZD4054Placebo
Time to Use of Opiates16.7 (7.3 to 27.0)14.8 (7.9 to 25.8)
SecondaryIncidence of Skeletal Related Events

Median time (in months) from randomisation until occurrence of a skeletal related event, where skeletal related event is defined as the first occurrence of a pathological fracture, a vertebral compression fracture not related to trauma, prophylactic surgery or radiation for impending fracture or spinal cord compression, or a spinal cord compression, using the Kaplan-Meier method.

Time frame:
From date of randomization until occurrence of a skeletal related event, assessed up to 31 months
Reported as:
Median · Months
Incidence of Skeletal Related Events
MonthsZD4054Placebo
Incidence of Skeletal Related Events18.4 (9.6 to 30.6)17.1 (9.3 to 25.8)
SecondaryBone Metastases Formation

Median time (in months) from randomisation to appearance of ≥4 new bone lesions using the Kaplan-Meier method

Time frame:
Patients were assessed every 12 weeks
Reported as:
Median · Months
Bone Metastases Formation
MonthsZD4054Placebo
Bone Metastases Formation15.1 (7.2 to 25.5)11.9 (7.0 to 22.5)
SecondaryHealth Related Quality of Life

Median time (in months) from randomisation until deterioration of Health related Quality of Life using the Kaplan-Meier method, where deterioration is defined as a change from baseline of less than or equal to -6 points in Total FACT-P score maintained for 2 consecutive visits.

Time frame:
Patients were assessed at every visit
Reported as:
Median · Months
Health Related Quality of Life
MonthsZD4054Placebo
Health Related Quality of Life5.5 (2.8 to 9.1)5.5 (2.8 to 9.1)
SecondaryTime to Prostate-specific Antigen (PSA) Progression

Median time (in months) from randomisation to first PSA value \>50% higher than baseline of at least 5ng/ml seen in at least 2 consecutive PSA values at least 2 weeks apart using the Kaplan-Meier method.

Time frame:
Patients were assessed every 12 weeks
Reported as:
Median · Months
Time to Prostate-specific Antigen (PSA) Progression
MonthsZD4054Placebo
Time to Prostate-specific Antigen (PSA) Progression5.6 (2.9 to 11.1)5.6 (2.8 to 11.4)
SecondaryTime to Pain Progression

Median time (in months) from randomisation to first assessment of an increased pain event, where increased pain event is defined as the first of a patient requiring opiate medication for duration of ≥1 week for pain due to prostate cancer metastasis, pain due to metastasis that has an increase in the worst pain item of the Brief Pain Inventory (BPI) from baseline to a minimum score of 5 with no decrease in analgesic use, or pain due to metastasis requiring radionuclide therapy, radiation therapy or surgery.

Time frame:
Patients were assessed every 12 weeks
Reported as:
Median · Months
Time to Pain Progression
MonthsZD4054Placebo
Time to Pain Progression9.0 (3.3 to 19.4)8.4 (3.4 to 19.1)
SecondaryTime to Initiation of Chemotherapy

Median time (in months) from randomisation to first administration of any chemotherapy using the Kaplan-Meier method

Time frame:
Patients were assessed every 12 weeks
Reported as:
Median · Months
Time to Initiation of Chemotherapy
MonthsZD4054Placebo
Time to Initiation of Chemotherapy11.4 (5.8 to 18.5)10.6 (6.0 to 18.2)
SecondaryPharmacokinetic Characteristics of ZD4054
Time frame:
PK samples were performed at randomisation, Week 4, Week 8 and Week 12
Reported as:
Least squares mean · Plasma concentration versus time

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ZD4054—98/298 (32.9%)257/298 (86.2%)
Placebo—105/295 (35.6%)221/295 (74.9%)
Most frequent serious events
Showing 10 of 171
Most frequent serious events
EventZD4054Placebo
DeathGeneral disorders2/2987/295
AnaemiaBlood and lymphatic system disorders6/2981/295
Cardiac FailureCardiac disorders6/2980/295
PneumoniaInfections and infestations6/2981/295
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders5/2982/295
Renal Failure AcuteRenal and urinary disorders1/2984/295
Pleural EffusionRespiratory, thoracic and mediastinal disorders4/2980/295
Febrile NeutropeniaBlood and lymphatic system disorders2/2983/295
NeutropeniaBlood and lymphatic system disorders2/2983/295
SepsisInfections and infestations3/2983/295
Most frequent other events
Showing 10 of 31
Most frequent other events
EventZD4054Placebo
Oedema PeripheralGeneral disorders132/29856/295
HeadacheNervous system disorders92/29837/295
NauseaGastrointestinal disorders62/29844/295
ConstipationGastrointestinal disorders61/29851/295
FatigueGeneral disorders58/29852/295
Nasal CongestionRespiratory, thoracic and mediastinal disorders48/2989/295
DiarrhoeaGastrointestinal disorders28/29846/295
AnaemiaBlood and lymphatic system disorders46/29833/295
Decreased AppetiteMetabolism and nutrition disorders44/29837/295
Back PainMusculoskeletal and connective tissue disorders35/29837/295

Baseline characteristics

Age, Continuous
Age, Continuous(Years)ZD4054PlaceboTotal
Overall70.2 ± 7.870.9 ± 8.670.5 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)ZD4054PlaceboTotal
Female000
Male299295594
08

Study locations

199 sites
  • Research Site
    Tucson, Arizona, United States
  • Research Site
    Greenbrae, California, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Palm Springs, California, United States
  • Research Site
    San Mateo, California, United States
  • Research Site
    Norwich, Connecticut, United States
  • Research Site
    Washington, District of Columbia, United States
  • Research Site
    Gainsville, Florida, United States
  • Research Site
    Port St.Lucie, Florida, United States
  • Research Site
    Des Moines, Iowa, United States
  • Research Site
    Canton, Ohio, United States
  • Research Site
    Pittsburgh, Pennsylvania, United States
  • Research Site
    Nashville, Tennessee, United States
  • Research Site
    Salt Lake City, Utah, United States
  • Research Site
    Burlington, Vermont, United States
  • Research Site
    Norfolk, Virginia, United States
  • Research Site
    Seattle, Washington, United States
  • Research Site
    Wheeling, West Virginia, United States
  • Research Site
    Milwaukee, Wisconsin, United States
  • Research Site
    Buenos Aires, Buenos Aires Province, Argentina
  • Research Site
    Santa Fe, Santa Fe Province, Argentina
  • Research Site
    Hornsby, New South Wales, Australia
  • Research Site
    St Leonards, New South Wales, Australia
  • Research Site
    Redcliffe, Queensland, Australia
  • Research Site
    Ashford, South Australia, Australia
  • Research Site
    Subiaco, Western Australia, Australia
  • Research Site
    Graz, Austria
  • Research Site
    Wels, Austria
  • Research Site
    Brussels, Belgium
  • Research Site
    Gent, Belgium
  • Research Site
    Kortrijk, Belgium
  • Research Site
    Leuven, Belgium
  • Research Site
    Fortaleza, Ceara, Brazil
  • Research Site
    Goiania, Goias, Brazil
  • Research Site
    Belo Horizonte, Minas Gerais, Brazil
  • Research Site
    Curitiba, Parana, Brazil
  • Research Site
    Porto Alegre, Rio Grande do Sul, Brazil
  • Research Site
    Ribeirao Preto, Sao Paulo, Brazil
  • Research Site
    Santo Andre, Sao Paulo, Brazil
  • Research Site
    Sao Paulo, Brazil
  • Research Site
    Calgary, Alberta, Canada
  • Research Site
    Edmonton, Alberta, Canada
  • Research Site
    Vancouver, British Columbia, Canada
  • Research Site
    Kentville, Nova Scotia, Canada
  • Research Site
    Barrie, Ontario, Canada
  • Research Site
    Burlington, Ontario, Canada
  • Research Site
    Hamilton, Ontario, Canada
  • Research Site
    Kitchener, Ontario, Canada
  • Research Site
    London, Ontario, Canada
  • Research Site
    Mississauga, Ontario, Canada
  • Research Site
    North York, Ontario, Canada
  • Research Site
    Oakville, Ontario, Canada
  • Research Site
    Ottawa, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    Granby, Quebec, Canada
  • Research Site
    Laval, Quebec, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Point-Claire, Quebec, Canada
  • Research Site
    Quebec City, Quebec, Canada
  • Research Site
    Quebec, Canada
  • Research Site
    Haidian District, Beijing, China
  • Research Site
    Xi Cheng District, Beijing, China
  • Research Site
    Xicheng District, Beijing, China
  • Research Site
    Wuhan, Hubei, China
  • Research Site
    Nanjing, Jiangsu, China
  • Research Site
    Pudong New Area, Shanghai, China
  • Research Site
    Shanghai, Shanghai, China
  • Research Site
    Xuhui District, Shanghai, China
  • Research Site
    Xi'an, Shanxi, China
  • Research Site
    Prague 4, Prague, Czech Republic
  • Research Site
    Prague 6, Prague, Czech Republic
  • Research Site
    Brno, Czech Republic
  • Research Site
    Olomouc, Czech Republic
  • Research Site
    Usti nad Labem, Czech Republic
  • Research Site
    Aalborg, Denmark
  • Research Site
    Aarhus, Denmark
  • Research Site
    Herlev, Denmark
  • Research Site
    Kobenhavn, Denmark
  • Research Site
    Joensuu, Finland
  • Research Site
    Kajaanintie, Finland
  • Research Site
    Tampere, Finland
  • Research Site
    Montpellier, France
  • Research Site
    Paris, France
  • Research Site
    Poitiers Cedex, France
  • Research Site
    Suresnes, France
  • Research Site
    Toulouse, France
  • Research Site
    Villejuif, France
  • Research Site
    Planegg, Muenchen, Germany
  • Research Site
    Kirchheim, Teck, Germany
  • Research Site
    Augsburg, Germany
  • Research Site
    Bad Gegeberg, Germany
  • Research Site
    Berlin, Germany
  • Research Site
    Emmendingen, Germany
  • Research Site
    Leipzig, Germany
  • Research Site
    Luebeck, Germany
  • Research Site
    Mannheim, Germany
  • Research Site
    Muenchen, Germany
  • Research Site
    Reutlingen, Germany
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Shatin, Hong Kong

Showing the first 100 of 199 sites across 31 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Jul 2010 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2007
First posted
Nov 6, 2007
Start
Nov 2007
Primary completionActual
Jul 2010
CompletionActual
Aug 2011
Results first posted
May 31, 2012
Last update
Feb 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00554229
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 6, 2007
Start date
Nov 2007
Primary completion
Jul 2010
Completion
Aug 2011
Results posted
May 31, 2012
Last update
Feb 8, 2016

Study contacts

Martin Gleave, MD, FRCSC, FACS
principal investigator · The Prostate Centre at Vancouver General Hospital
Joel B Nelson, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZD4054

Start the discussion